These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28302543)

  • 1. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy.
    Trabattoni D; Clerici M; Centanni S; Mantero M; Garziano M; Blasi F
    Pulm Pharmacol Ther; 2017 Jun; 44():24-29. PubMed ID: 28302543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia.
    Esposito S; Garziano M; Rainone V; Trabattoni D; Biasin M; Senatore L; Marchisio P; Rossi M; Principi N; Clerici M
    J Transl Med; 2015 Sep; 13():288. PubMed ID: 26335787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression.
    Carta S; Silvestri M; Rossi GA
    Ital J Pediatr; 2013 May; 39():29. PubMed ID: 23663325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunomodulatory molecule pidotimod induces the expression of the NOD-like receptor NLRP12 and attenuates TLR-induced inflammation.
    Fogli M; Caccuri F; Iaria ML; Giagulli C; Corbellini S; Campilongo F; Caruso A; Fiorentini S
    J Biol Regul Homeost Agents; 2014; 28(4):753-66. PubMed ID: 25620184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulating activity of Pidotimod in children with Down syndrome.
    Zuccotti GV; Mameli C; Trabattoni D; Beretta S; Biasin M; Guazzarotti L; Clerici M
    J Biol Regul Homeost Agents; 2013; 27(1):253-8. PubMed ID: 23489705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children.
    Caramia G; Clemente E; Solli R; Mei V; Cera R; Carnelli V; Venturoli V; Corsini A
    Arzneimittelforschung; 1994 Dec; 44(12A):1480-4. PubMed ID: 7857347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections.
    Zhao N; Liu C; Zhu C; Dong X; Liu X
    Expert Rev Anti Infect Ther; 2019 Oct; 17(10):803-818. PubMed ID: 31603361
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
    Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F
    Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence.
    Marseglia GL; Gelardi M; Santus P; Ciprandi G
    Minerva Med; 2024 Aug; 115(4):503-515. PubMed ID: 39016527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3).
    Caccuri F; Bugatti A; Corbellini S; Roversi S; Zani A; Mazzuca P; Marsico S; Caruso A; Giagulli C
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31653015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of pidotimod in combination with bacterial lysates in the treatment of the pfapa (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) syndrome].
    Buongiorno A; Pierossi N
    Minerva Pediatr; 2015 Jun; 67(3):219-26. PubMed ID: 25941128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.
    Giagulli C; Noerder M; Avolio M; Becker PD; Fiorentini S; Guzman CA; Caruso A
    Int Immunopharmacol; 2009 Nov; 9(12):1366-73. PubMed ID: 19712757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pidotimod: a reappraisal.
    Riboldi P; Gerosa M; Meroni PL
    Int J Immunopathol Pharmacol; 2009; 22(2):255-62. PubMed ID: 19505378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pidotimod in allergic diseases.
    Manti S; Parisi GF; Papale M; Leonardi S
    Minerva Pediatr; 2020 Oct; 72(5):358-363. PubMed ID: 32731733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pidotimod and Immunological Activation in Individuals Infected with HIV.
    Ucciferri C; Falasca K; Reale M; Tamburro M; Auricchio A; Vignale F; Vecchiet J
    Curr HIV Res; 2021; 19(3):260-268. PubMed ID: 33430735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals.
    Nie XM; Li YS; Yang ZW; Wang H; Jin SY; Jiao Y; Metersky ML; Huang Y
    Clin Microbiol Infect; 2018 Jun; 24(6):658.e1-658.e6. PubMed ID: 28970157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.